DANBURY, Conn. and WESTLAKE VILLAGE, Calif. - MannKind (NASDAQ:MNKD) Corporation (NASDAQ:MNKD), a biopharmaceutical company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, announced today that it will present new clinical data from its INHALE-3 study at the 17th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Florence.
The data presentation, scheduled for Friday, will focus on the efficacy of inhaled insulin in managing post-meal blood glucose levels compared to subcutaneous rapid-acting analogues.
The INHALE-3 study is a Phase 4 clinical trial conducted in the United States, assessing the performance of MannKind's inhaled insulin product, Afrezza, plus basal insulin, against the standard of care for diabetes management. The trial includes participants over 18 years old with Type 1 Diabetes (T1D) and utilizes continuous glucose monitoring to evaluate mealtime glucose control and A1c levels.
Dr. Irl B. Hirsch, the study's protocol chair and a noted diabetes expert from the University of Washington, will deliver the oral presentation, showcasing results from a standardized meal challenge. The challenge examined post-prandial glucose levels, the area under the curve (AUC), time to peak glucose levels, and the frequency of post-meal hypoglycemia in both the inhaled insulin and subcutaneous insulin groups.
The upcoming presentation builds upon preliminary findings from MannKind's earlier ABC study, which suggested that a higher initial dose of inhaled insulin could significantly reduce post-prandial glucose levels and peak faster than standard care. The INHALE-3 study further explores these findings with a larger comparator group and over a more extended treatment regimen.
The study is a 17-week randomized controlled trial with a subsequent 13-week extension period. More detailed results are expected to be provided after the conference. Interested parties can find additional information about the INHALE-3 study, including its design and objectives, on ClinicalTrials.gov under identifier NCT05904743.
MannKind emphasizes its commitment to advancing treatment options for diabetes and other serious diseases through its proprietary dry-powder formulations and inhalation devices.
This news is based on a press release statement from MannKind Corporation.
InvestingPro Insights
As MannKind Corporation (NASDAQ:MNKD) gears up to present its latest clinical data, the financial metrics from InvestingPro paint a picture of a company with significant movements in the market. A notable 99.42% revenue growth over the last twelve months as of Q1 2023 indicates a robust expansion in MannKind's financial performance. This growth is further reflected in the company's gross profit margin, which stands at an impressive 68.45% for the same period. Such figures suggest a strong underlying business capable of generating substantial margins on its products.
Investors looking at the stock's recent performance will find that MannKind has experienced a strong return over the last month, with a price total return of 43.08%. This momentum is an essential consideration for those assessing the company's short-term investment potential. For more in-depth analysis, including additional InvestingPro Tips such as the company's moderate level of debt and the expectation of net income growth this year, visit https://www.investing.com/pro/MNKD. It's worth noting that MannKind is currently trading at a high EBITDA valuation multiple, which may factor into investment decisions.
For those interested in further insights, InvestingPro offers an array of additional tips, with a total of 12 additional tips available, ranging from the stock's RSI indicating overbought territory to predictions of profitability. To access these insights and enhance your investment strategy, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.